Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
Level 5 - mechanism / opinion, no new human data
Animal model study (streptozocin-induced diabetic rats)
PubMed 3917257 · doi:10.2337/diab.34.1.15
What was done
The authors investigated the effect of the aldose reductase inhibitor sorbinil (a spirohydantoin) initiated after stage I cataract formation in streptozocin-induced diabetic rats. Lens physiology, biochemistry (sorbitol, glucose, myo-inositol), and structural morphology via quantitative scanning electron microscopy were assessed during ongoing hyperglycemia.
What was found
No numerical values or statistical estimates were reported in the abstract. Sorbinil arrested cataract progression and promoted lens repair despite sustained hyperglycemia and elevated lens glucose. Reported changes included normalization of lens sorbitol, stabilization and recovery of fiber contour and interdigitation, production of new fibers, and partial restoration of lens myo-inositol.
Why it matters
The findings provide preclinical evidence that aldose reductase inhibition can reverse early-stage cataractous structural and biochemical alterations independently of glycemic control.
Limits
This is an animal study in chemically induced diabetic rats, which limits direct extrapolation to human diabetic cataracts. Sample size, drug dosage, duration of follow-up, and specific quantitative metrics were not reported in the abstract.
Cited by
- supports Aldose reductase inhibitors effectively prevent cataractogenesis and treat complications of diabetes in rodent models.